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Key questions 33 
What is already known about this subject? 34 
Patients with suspected acute myocardial infarction (AMI) in the setting of left bundle branch 35 
block (LBBB) present an important diagnostic and therapeutic challenge to the clinician.  36 
What does this study add? 37 
Specific ECG criteria in LBBB patients including concordant ST-segment elevation (criteria 38 
1) or depression (criteria 2) or pronounced discordant ST-segment elevation (criteria 3) in 39 
specific ECG leads and an alternative ECG criteria including ST-segment depression or 40 
elevation discordant with the QRS complex with a magnitude of at least 25% of the QRS 41 
complex (alternative criteria 3) together with suggested (h)s-cTn thresholds (e.g. hs-cTnT 42 
≥42ng/l at presentation) allow an accurate and immediate triage to coronary angiography in 43 
patients with LBBB and symptoms suggestive of AMI.   44 
How might this impact on clinical practice? 45 
An integrated triage-algorithm including specific ECG criteria with high specificity, as well 46 
as hs-cTnT/I concentrations at presentation and their 0/1h- or 0/2h-changes provides high 47 
diagnostic accuracy and efficacy helping in the selection of patients for immediate and/or 48 
early coronary angiography. 49 
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ABSTRACT  50 
Objective: Patients with suspected acute myocardial infarction (AMI) in the setting of left 51 
bundle branch block (LBBB) present an important diagnostic and therapeutic challenge to the 52 
clinician.  53 
Methods: We prospectively evaluated incidence of AMI, and diagnostic performance of 54 
specific electrocardiographic (ECG) and high-sensitivity cardiac troponin (hs-cTn) criteria in 55 
patients presenting with chest discomfort to 26 emergency departments in three international, 56 
prospective, diagnostic studies. The final diagnosis of AMI was centrally adjudicated by two 57 
independent cardiologists according to the universal definition of myocardial infarction.  58 
Results: Among 8830 patients, LBBB was present in 247 patients (2.8%). AMI was the final 59 
diagnosis in 30% of patients with LBBB, with similar incidence in those with known LBBB 60 
versus those with presumably new LBBB (29% vs 35%, p=0.42). ECG criteria had low 61 
sensitivity (1-12%), but high specificity (95-100%) for AMI. The diagnostic accuracy as 62 
quantified by the receiver-operating-characteristics curve of hs-cTnT and hs-cTnI 63 
concentrations at presentation (AUC 0.91; 95%CI 0.85–0.96 and 0.89; 95% CI 0.83-0.95) as 64 
well as that of their 0/1h- and 0/2h-changes was very high. A diagnostic algorithm combining 65 
ECG criteria with hs-cTnT/I concentrations and their absolute changes at 1h or 2h derived in 66 
cohort 1 (45 of 45 (100%) of patients with AMI correctly identified), showed high efficacy 67 
and accuracy when externally validated in cohort 2&3 (28 of 29 patients, 97%). 68 
Conclusion: Most patients presenting with suspected AMI and LBBB will be found to have 69 
diagnoses other than AMI. Combining ECG criteria with hs-cTnT/I testing at 0/1h or 0/2h 70 
allows early and accurate diagnosis of AMI in LBBB. 71 
Keywords 72 
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INTRODUCTION 77 
Patients with symptoms suggestive of acute myocardial infarction (AMI) account for 78 
approximately 10% of all emergency department (ED) consultations. Rapid identification of 79 
AMI as life-threatening disorder is important for the early initiation of highly effective, 80 
evidence-based therapy.(1)(2)(3) Patients presenting with suspected AMI and left bundle 81 
branch block (LBBB) to the ED represent a unique diagnostic and therapeutic challenge, as 82 
altered ventricular depolarization masks changes in ventricular repolarization associated with 83 
myocardial ischemia.(2)  84 
In patients presenting with ST-segment elevation MI (STEMI), who usually can be rapidly 85 
identified with the 12-lead ECG, enormous improvements in outcomes have been 86 
achieved.(1)(2) These patients derive major benefit from immediate coronary 87 
reperfusion.(1)(2) It is currently unknown, how AMI can best be diagnosed early in patients 88 
presenting with suspected AMI and LBBB.(1)(2) This major uncertainty is highlighted by 89 
divergent recommendations given by the respective clinical practice guidelines in the United 90 
States and Europe.(1)(2)  Current European Society of Cardiology (ESC) guidelines stated 91 
that patients with LBBB should be managed in a way similar to STEMI patients.(2) In 92 
contrast, current American Heart Association (AHA) and American College of Cardiology 93 
(ACC) guidelines interpret LBBB not to be diagnostic for AMI.(1) Too liberal interpretation 94 
of LBBB could lead to thousands of unnecessary cardiac catheterization laboratory 95 
activations and thousands of patients inappropriately given thrombolytic therapy each year, 96 
increased risk of complications related to inappropriate invasive procedures, prolonged 97 
hospitalization, higher treatment costs and decreased quality of life for patients.(4)(5)(6) In 98 
contrast, too restrictive interpretation of LBBB could withhold life-saving immediate 99 
reperfusion therapy from patients with large AMIs and could ultimately increase 100 
mortality.(4)(7) 101 
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In order to address this important gap in knowledge, we aimed to first, evaluate the 102 
incidence of AMI among patients with suspected AMI and LBBB in the recorded at ED 103 
presentation, and second, to develop a comprehensive strategy for the early diagnosis of AMI 104 
in patients with LBBB.(4)(8)(9) 105 
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METHODS 106 
Study design and oversight 107 
We enrolled adult patients presenting with suspected AMI to the ED in three large 108 
prospective multicenter diagnostic studies carried out according to the principles of the 109 
Declaration of Helsinki and approved by the local ethics committees. These are Advantageous 110 
Predictors of Acute Coronary Syndrome Evaluation (APACE) (10)(11)(12) Accelerated 111 
Diagnostic Protocol to Assess patients with chest Pain symptoms using contemporary 112 
Troponins as the only biomarker (ADAPT),(13) and High-sensitivity cardiac Troponin T 113 
assay for RAPID rule-out of AMI (TRAPID-AMI)(14). Written informed consent was 114 
obtained from all patients (Online Table 1). 115 
The authors designed the study, gathered, analyzed and reported the data according to 116 
the STARD guidelines for studies of diagnostic accuracy(15) (Online Table 2), vouch for the 117 
data and analysis, wrote the paper, and made the decision to submit it for publication. The 118 
sponsors had no role in the design of the study, the analysis of the data, the preparation of the 119 
manuscript, or the decision to submit the manuscript for publication. 120 
 121 
Methodology of all three cohorts 122 
In all three cohorts, we included unselected patients presenting to the ED with acute 123 
chest discomfort. All patients underwent a clinical assessment that included standardized and 124 
detailed medical history including assessment of chest pain characteristics, vital signs, 125 
physical examination, 12-lead ECG, continuous ECG rhythm monitoring, pulse oximetry, 126 
standard blood test, and chest radiography and echocardiography if indicated. Treatment of 127 
patients was left to discretion of the attending physician. 128 
8 
 
Detailed methodical descriptions of all 3 cohorts including study -design, -dates and -129 
centers, eligibility criteria and study population, routine clinical assessment, adjudication of 130 
final diagnoses, follow-up and clinical endpoints are shown in the Appendix. An overview of 131 
study specific characteristics including investigational high-sensitivity cardiac troponin (hs-132 
cTn) measurements, adjudication of final diagnoses and specific ECG criteria for all 3 cohorts 133 
are shown in Online Table 1 and described in detail within the Appendix. 134 
 135 
Adjudication of specific ECG criteria 136 
ECG adjudication was performed centrally for all 3 cohorts by at least 2 independent 137 
cardiologists blinded to all clinical information and using predefined criteria.(16)(17) LBBB 138 
criteria were a QRS duration of more than 120ms, dominant S wave in V1, broad monophasic 139 
R wave in lateral leads (I, aVL, V5-V6), an absence of Q waves in lateral leads (I, V5-V6; 140 
small Q waves were still allowed in aVL) and prolonged R wave peak time > 60ms in left 141 
precordial leads (V5-6).  142 
ECG criteria 1 to 3(16) included ST-segment elevation of 0.1 mV or more concordant 143 
with the QRS complex in any lead (ECG criteria 1, 5 points), concordant ST-segment 144 
depression of 0.1 mV or more in lead V1, V2, or V3 (ECG criteria 2, 3 points) and ST-145 
segment elevation of 0.5 mV or more discordant with the QRS complex in any lead (ECG 146 
criteria 3, 2 points; Online Figure 1A). A score of ≥3 was suggested for the diagnosis of 147 
acute coronary occlusion within the original publication (ECG score ≥3).(16) The alternative 148 
ECG criteria 3 (17) were proposed to be superior to the original ECG criteria 3 and is defined 149 
as a negative ST/S ratio <-0.25 and at least 0.1 mV of ST segment elevation in any lead, 150 
(alternative ECG criteria 3, 2 points, Online Figure 1B)(18). Again, a score of ≥3 was 151 
suggested for the diagnosis of acute coronary occlusion (alternative ECG score ≥3). In case of 152 
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presence of LBBB on a previous ECG, LBBB was classified as known. Otherwise it was 153 
classified as presumably new. A differentiation between new and new presumably LBBB was 154 
not possible, because exact onset of LBBB could not be determined in most patients. 155 
Differentiation between known and presumably new LBBB was possible in cohort #1 by 156 
retrieving previous ECG recordings from the electronic ECG storage systems of the 157 
participating institutions as well as the general practitioner in the vast majority of patients, but 158 
not in cohort #2 and #3.  159 
Case studies for three patients presenting with suspected AMI and LBBB are 160 
described in Online Figure 2, including their clinical presentation, medical history, ECG at 161 
presentation, hs-cTnT concentrations, coronary angiography results, follow-up information 162 
and adjudication diagnoses. 163 
 164 
Statistical analysis 165 
The data are expressed as medians ± interquartile range (IQR) for continuous 166 
variables, and for categorical variables as numbers and percentages. All variables between 167 
known LBBB and presumably new LBBB or LBBB with or without AMI were compared by 168 
Student`s t Test or Mann-Whitney-U test for continuous variables or Pearson chi-square or 169 
Fisher’s Exact test for categorical variables. Receiver-operating characteristics (ROC) curves 170 
were constructed to assess the sensitivity and specificity for concentrations of hs-cTnT/I at 171 
presentation and their 1h or 2h absolute changes. A positive predictive value (PPV) of 80% 172 
was considered necessary to proceed with early coronary angiography(19) for the derivation 173 
of cut-off concentrations. In cohort #1 (derivation cohort) we performed a univariate 174 
regression analysis using the selection operator LASSO to find predictors for the model. 175 
Variables who entered this model have been previously selected based on their availability in 176 
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all 3 cohorts, shown differences within the baseline characteristics tables and based on their 177 
clinical importance. Additionally, the numbers of variables were restricted to the number of 178 
events (AMI in patients with LBBB). In cohort #2 and cohort #3 (validation cohorts) we used 179 
the same variables as in cohort #1, if they have shown a statistically significant difference. All 180 
hypothesis testing was two-tailed, and P values of less than 0.05 were considered to indicate 181 
statistical significance. All statistical analyses were performed with the use of IBM SPSS 182 
Statistics for Windows, version 24.0 (SPSS Version 24, Inc Chicago, IL).  183 
 184 
 185 
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 190 
 191 
 192 
 193 
 194 
 195 
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 199 
 200 
Results 201 
Study population 202 
Overall, 8830 patients were available for analysis (Online Figure 3). LBBB was present in 203 
247 patients (2.8%; Figure 1A)). AMI was the final diagnosis in 30% (75 of 247 patients, 204 
Figure 1B) of patients with LBBB, with similar incidence in those with known LBBB versus 205 
those with presumably new LBBB (29% vs 35%, p=0.42). Patients with known LBBB had 206 
similar baseline characteristics as those with presumably new LBBB. (Online Table 3) 207 
Patients with LBBB were older, had more cardiovascular risk factors and more often 208 
preexisting cardiac disease, including coronary artery disease (CAD) in 54% as compared to 209 
33% in the overall population (Table 1, Online Tables 4-8).  210 
 211 
Echocardiography 212 
Echocardiographic findings were similar in LBBB patients with AMI as compared to LBBB 213 
patients without AMI (Online Table 9). Most patients with LBBB had moderately reduced 214 
left ventricular ejection fraction (LVEF, median 40%), a dilated left atrium (70%), left 215 
ventricular hypertrophy (56%) and wall motion abnormalities (79%). 216 
 217 
Coronary intervention 218 
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In patients with AMI and LBBB coronary intervention were performed in the left anterior 219 
descending coronary artery in 16%, in the left circumflex artery in 13%, in a venous bypass 220 
graft in 8.9%, and in the right coronary artery in 4.4% (Table 1). 221 
 222 
 223 
ECG criteria 224 
Seventeen patients (12%) fulfilled at least one of the specific ECG criteria for AMI detection. 225 
Each criteria or their combination in a score had a sensitivity ranging from 1% to 12% and a 226 
specificity ranging from 95% to 100% (Table 2, Online Figure 4A). We found no differences 227 
for specific ECG criteria pertaining to the culprit lesion. Thirteen percent of patients with 228 
specific ECG criteria were found to have the culprit lesion in the left main vessel, RIVA, 229 
RCX or ACD, respectively. 230 
 231 
Hs-cTnT/I 232 
Blood concentrations of hs-cTnT and (h)s-cTnI at presentation and their early absolute 233 
changes were significantly higher in LBBB patients with AMI as compared to those with 234 
other final diagnoses (Online Figure 5). Diagnostic accuracy as quantified by the area under 235 
the ROC curve (AUC) was very high (at presentation AUC for hs-cTnT 0.91; 95%CI 0.85–236 
0.96; and AUC for hs-cTnI 0.89, 95% CI 0.83-0.95; Table 3). Hs-cTnT levels ≥42ng/L (hs-237 
cTnI ≥45ng/L, s-cTnI ≥52ng/L) provided a PPV of 80% (95% CI, 64-90%) for AMI and 238 
together with known CAD (odds ratio 4.6, 95%CI 2.0–10.4) predicted AMI in multivariate 239 
analysis in LBBB patients (odds ratio 31.4, 95%CI 10–98.7; Table 3; Online Table 10, 240 
Online Figure 4B). 241 
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Suggested diagnostic work-up 242 
In cohort #1 at least one specific ECG criteria were positive in 17/140 (12%) of 243 
patients with LBBB and suspected AMI, of whom 8 (47%) patients had an AMI. 38/140 244 
patients had hs-cTnT concentration at presentation ≥ 42ng/L, of whom 29 (76%) patients had 245 
an AMI. 11/140 (8%) had an hs-cTnT 0/1h absolute change concentration ≥ 3ng/L, of whom 246 
8 (73%) had an AMI (Figure 1). In both validation cohorts using this step-by-step approach 247 
resulted in similar findings and high accuracy to identify patients for the suggested work-up. 248 
(Figure 2 and 3). 249 
The performance of the individual ECG criteria, of hs-cTnT and hs-cTnI in general, 250 
and their respective cut-off concentrations optimized for use in patients with LBBB in 251 
particular, were similar among the three cohorts. 252 
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DISCUSSION 253 
This analysis is based on three large prospective multicenter diagnostic studies with 254 
central adjudication of AMI by independent cardiologists applying the universal definition of 255 
AMI(3). It was performed to contribute to advancing the clinical care of patients presenting 256 
with symptoms suggestive of AMI and LBBB to the ED. We report five major findings. 257 
First, 2.8% of patients presenting with suspected AMI to the ED had LBBB. These 258 
patients were older and more often had preexisting cardiovascular disorders including CAD. 259 
Second, the majority of patients presenting with suspected AMI and LBBB were finally found 260 
to have non-cardiac disorders and cardiac disorders other than AMI. The incidence of AMI  261 
was 30% in LBBB patients, and similar in patients with known LBBB versus new/presumably 262 
new LBBB.  Third, specific ECG criteria had low sensitivity, but high specificity for AMI. 263 
Integrating the alternative ECG criteria 3 to the specific ECG score resulted in a sensitivity of 264 
12% and specificity of 97%. Fourth, diagnostic accuracy of hs-cTnT and hs-cTnI 265 
concentrations at ED presentation and their early changes within 1h or 2h was very high. In 266 
addition, together with a history of known CAD hs-cTnT/I concentrations at presentation 267 
predicted the presence of AMI in multivariate analysis. Hs-cTnT concentrations at 268 
presentation with a predefined PPV of at least 80% for AMI were 42ng/L or higher (hs-cTnI 269 
≥45ng/L, s-cTnI ≥52ng/L). Interestingly, these (h)s-cTnT/I cut-off levels providing a PPV for 270 
AMI of 80% in patients with LBBB were similar to those recommended in current ESC 271 
guidelines for the rule-in of AMI in general. (20) Fifth, a novel triage algorithm integrating 272 
specific ECG criteria as the first step, hs-cTnT/I at presentation as the second, and the 0/1h 273 
absolute change in hs-cTnT/I as the third step, provided high accuracy and efficacy for the 274 
early detection of AMI and thereby for the selection of patients for immediate and early 275 
coronary angiography in both the derivation and external validation cohort. 276 
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 These findings from 8830 patients presenting with suspected AMI to the ED extend 277 
and corroborate previous work on patients with LBBB.(16)(17)(21)(22)(23)(24)(25)(26) 278 
Results derived from selected patients enrolled in clinical trials of new pharmacologic 279 
therapies had indicated that patients with likely AMI who have new or presumably new 280 
LBBB should undergo rapid reperfusion therapy.(2) This strategy has recently been 281 
challenged by retrospective single-center studies from unselected ED cohorts or STEMI-282 
networks suggesting that most patients with symptoms suggestive of AMI with new or 283 
presumably new LBBB do not have AMI.(23)(24)(27)(28)(29)(30) However, these studies 284 
had important methodological limitations including retrospective design, use of administrative 285 
coding for AMI, use of cardiac biomarkers with poor sensitivity such as CK-MB or previous 286 
generation cTn, and lack of adherence to the universal definition of AMI.(1)(2)  287 
 Our study overcomes these limitations and provides detailed guidance on how 288 
currently available diagnostic tools can best be used in patients with LBBB to balance the 289 
benefits and risks associated with early coronary angiography.(1)(2) Only one third of 290 
patients presenting with symptoms suggestive of AMI and LBBB to the ED will be found to 291 
have AMI as final diagnosis, irrespective of known or presumably new LBBB. Due to their 292 
high specificity, specific ECG criteria should be used to immediately triage patients towards 293 
rule-in of AMI and immediate coronary angiography such as in STEMI patients (around 6-294 
12% of patients with LBBB). Patients not meeting these ECG criteria do have only a slightly 295 
higher overall incidence of AMI as compared to patients without LBBB and should undergo 296 
standard testing for hs-cTn.(1)(2)(8)(13)(14) Already the measurement at presentation 297 
provides very high diagnostic accuracy and allows to rapidly rule-in additional patients for 298 
early coronary angiography, if hs-cTn blood concentrations are substantially elevated (≈15% 299 
of patients with LBBB).(8)(13)(14)(20) In all remaining patients, the second hs-cTn blood 300 
concentration determined 1h to 2h after presentation will allow to identify additional AMI 301 
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patients in case of a relevant absolute change and triage them for early coronary angiography. 302 
In patients not meeting any of the three rule-in criteria, the likelihood of having AMI is very 303 
low. Still, as with all other early triage algorithm, detailed clinical assessment including chest 304 
pain characteristics and possibly additional hs-cTnT/I measurements at 3h helps selecting the 305 
most appropriate cardiac imaging modality to follow: echocardiography, non-invasive stress 306 
imaging, coronary computed tomography angiography, coronary angiography, or none in 307 
patients in whom the diagnostic work-up already has established a definite alternative cause 308 
of acute chest discomfort at that time such as pneumonia or pulmonary embolism (Figures 1-309 
3 and Online Figure 6A-B).(19)  310 
Among LBBB patients with AMI, culprit lesions most often were in the RIVA and 311 
RCX. This distribution differs from all-comers with AMI. (16)(17)(21)(22)(23)(24)(25)(26) 312 
Potential limitations of the present study merit consideration. First, while a relevant 313 
percentage of patients had LBBB recorded on a previous ECG and were classified as known 314 
LBBB, as in all previous studies, the exact onset of LBBB was unknown in many patients and 315 
LBBB had to be classified as new or presumably new in APACE. This inherent limitation can 316 
only be overcome in patients with implantable devices such as pacemakers and loop 317 
recorders. In cohort #2 and #3, limited data on previous ECGs were available, therefore 318 
differentiation between known LBBB and presumably new LBBB was not possible for all 319 
patients. Second, although all three studies tried to be broad in the exact definition of its 320 
inclusion criteria in order to reflect the clinical challenge, we wish to acknowledge that it is 321 
unclear whether the findings of this study can also be extrapolated to AMI patients presenting 322 
with uncommon symptoms such as e.g. exclusively with weakness.(31) Third, our findings 323 
were derived from patients presenting with symptoms suggestive of AMI to the ED. While 324 
our study designs ensure the generalizability to this setting, our findings may not apply to 325 
settings with a much lower pretest probability for AMI such as patients presenting to a 326 
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general practitioner, and settings with a much higher pretest probability such as patients in 327 
shock or after cardiac arrest transferred directly to a catheter laboratory. Additional studies are 328 
necessary in these settings. Fourth, this study required written informed consent. Accordingly, 329 
our findings may not apply to critically ill patients unable to provide informed consent, such 330 
as patients after cardiac arrest or patients in cardiogenic shock. These patients were eligible 331 
only in cohort #2, where a retrospective consent or a consent given by family members was 332 
possible. Unfortunately, this limitation also applies to diagnostic tests in general. Fifth, we 333 
cannot comment on LBBB in patients with terminal kidney failure, as these patients were 334 
excluded in cohort #1 and #3. 335 
In conclusion, most patients presenting with symptoms suggestive of AMI and LBBB to the 336 
ED will be found to have diagnoses other than AMI and should not be considered a STEMI 337 
equivalent. An integrated triage-algorithm including specific ECG criteria with high 338 
specificity, as well as hs-cTnT/I concentrations at presentation and their 0/1h- or 0/2h-339 
changes provides high diagnostic accuracy and efficacy helping in the selection of patients for 340 
immediate and/or early coronary angiography. 341 
 342 
Additional APACE, ADAPT, and TRAPID-AMI Investigators and contributors to this 343 
manuscript were: 344 
Petra Hillinger, MD1,2; Karin Grimm, MD1,2; Ursina Honegger, MSc1; Nicolas Schaerli, 345 
MD1,2; Nikola Kozhuharov, MD1,2; Samyut Shrestha, MD1,2; Claudia Stelzig, MSc1; Michael 346 
Freese, SN1; Zaid Sabti, MD1,2; Joan Walter, MD1,2; Lorraine Sazgary, MD1,2; Caroline 347 
Kulangara, PhD1; Kathrin Meissner, RN1; Deborah Mueller, MD1,2; Beatriz Lopez, MD2,3; 348 
Emilio Salgado, MD2,3; Esther Rodríguez Adrada, MD4; Damian Kawecki MD5; Jiri Parenica, 349 
MD6; Eva Ganovska, MD6; Katharina Rentsch, PhD7; Andreas Buser, MD8; Jens Lohrmann, 350 
18 
 
MD1; Roland Bingisser, MD9; Samyut Shrestha, MD1; Fabio Stallone, MD1; Roger 351 
Abaecherli, PhD1,2; James McCord, MD,10 Richard Nowak, MD11; Richard Body, PhD11,12; 352 
Christopher R. deFilippi, MD13; Robert H. Christenson, PhD14; Mauro Panteghini, MD15; 353 
Mario Plebani, MD16; Franck Verschuren, MD17; John French, PhD18; Silvia Weiser, PhD19; 354 
Carina Dinkel, PhD19; Dagmar I. Keller, MD20; Nicolas Geigy, MD21. 355 
 356 
1Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University 357 
Hospital Basel, Switzerland; 2GREAT network; 3Emergency department, Hospital Clinic, 358 
Barcelona, Catalonia, Spain; 4Emergency department, Hospital Clinico San Carlos, Madrid, 359 
Spain; 52nd Cardiology department, Zabrze, University Silesia, Katowice, Poland; 6University 360 
Hospital Brno, Czech Republic; 7Laboratory Medicine, University Hospital Basel, 361 
Switzerland; 8Blood Bank and Department of Hematology, University Hospital Base, 362 
Switzerland; 9Emergency Department, University Hospital Basel, Switzerland; 10Henry Ford 363 
Heart & Vascular Institute, Henry Ford Health System, Detroit, Michigan, USA; 11Emergency 364 
Department, Central Manchester University Hospitals NHS Foundation Trust, Manchester 365 
Academic Health Sciences Centre, Manchester, United Kingdom; 12Cardiovascular Sciences 366 
Research Group, University of Manchester, Oxford Road, Manchester, United Kingdom; 367 
13Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, 368 
USA; 14Department of Pathology, University of Maryland School of Medicine, Baltimore, 369 
Maryland, USA; 15Department of Biomedical and Clinical Sciences "Luigi Sacco," University 370 
of Milan Medical School, Milan, Italy; 16Department of Laboratory Medicine, University 371 
Hospital Padova, Italy; 17Cliniques Universitaires St-Luc and Universite Catholique de 372 
Louvain, Brussels, Belgium; 18Liverpool Hospital and University of New South Wales, 373 
Sydney, Australia; 19Roche Diagnostics Germany, Penzberg, Germany; 20Emergency 374 
Department, University Hospital Zürich, Switzerland; 21Emergency Department, 375 
Kantonsspital Liestal, Switzerland.. 376 
 377 
ACKNOWLEDGEMENTS 378 
19 
 
We thank the patients who participated in the study, the staff of the EDs, the research 379 
coordinators, and the laboratory technicians (particularly Esther Garrido, Irina Klimmeck, 380 
Christine Kruse, Sabrina Laule, and Fausta Chiaverio) for their most valuable efforts. 381 
 382 
Disclosures 383 
Dr. Mueller has received research grants from the Swiss National Science Foundation and the 384 
Swiss Heart Foundation, the European Union, the Cardiovascular Research Foundation Basel, 385 
8sense, Abbott, ALERE, Astra Zeneca, Beckman Coulter, Biomerieux, BRAHMS, Critical 386 
Diagnostics, Nanosphere, Roche, Siemens, Singulex, and the University Hospital Basel, as 387 
well as speaker or consulting honoraria from Abbott, ALERE, Astra Zeneca, BG Medicine, 388 
Biomerieux, BMS, Boehringer Ingelheim, BRAHMS, Cardiorentis, Daiichi Sankyo, Novartis, 389 
Roche, Sanofi, Singulex, and Siemens. Dr. Cullen reports grants from Roche and from 390 
Abbott, during the conduct of the study. Grants from Roche, grants and personal fees from 391 
Abbott Diagnostics, grants from Siemens, grants from Radiometer, personal fees from 392 
AstraZeneca, grants from Alere, outside the submitted work. Dr. Lindahl has served as a 393 
consultant for Roche Diagnostics, Beckman Coulter Inc., Siemens Healthcare Diagnostics, 394 
Radiometer Medical, bioMérieux Clinical Diagnostics, Philips Healthcare, and 395 
Fiomidiagnostics AB. Dr. Reichlin has received research grants from the Swiss National 396 
Science Foundation (PASMP3-136995), the Swiss Heart Foundation, the University of Basel, 397 
the Professor Max Cloetta Foundation and the Department of Internal Medicine, University 398 
Hospital Basel as well as speaker’s honoraria from Brahms and Roche. Dr. Giannitsis has 399 
received honoraria for lectures from Roche Diagnostics, BRAHMS, ThermoFisher and 400 
Mitsubishi Chemical Europe. Dr. Christ has received research support and speaking honoraria 401 
from Roche, ThermoFisher, and Novartis. Dr. Twerenbold reports speaker honoraria from 402 
Brahms and Roche. Dr. Parsonage reports grants from Roche and from Abbott, during the 403 
20 
 
conduct of the study and grants from Roche, grants and personal fees from Abbott 404 
Diagnostics, grants from Siemens, grants from Radiometer, personal fees from AstraZeneca, 405 
non-financial support from Bayer, personal fees from Hospira, grants from Alere, outside the 406 
submitted work. Dr. Rubini Gimenez has received speaking honoraria from Abbott and a 407 
research grant from the Swiss Heart Foundation. Dr. Boeddinghaus has received speaking 408 
Honoria from Siemens. Dr. Bendig is an employee of Roche Diagnostics. Dr. Pickering is 409 
supported by a Senior Research Fellowship from the Canterbury Medical Research 410 
Foundation, Emergency Care Foundation and Canterbury District Health. 411 
 All other authors declare that they have no conflict of interest with this study.  412 
Thomas Nestelberger, Jasper Boeddinghaus, Raphael Twerenbold, (cohort #1 and #3), Jaimi 413 
Greenslade (cohort #2), and Christian Müller had full access to all of the data in the study and 414 
take responsibility for the integrity of the data and the accuracy of the data analysis. 415 
The Corresponding Author has the right to grant on behalf of all authors and does grant on 416 
behalf of all authors, an exclusive licence (or nonexclusive for government employees) on a 417 
worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if 418 
accepted) to be published in HEART editions and any other BMJPGL products to exploit all 419 
subsidiary rights" 420 
 421 
Sources of Funding 422 
Cohort #1 (APACE) was supported by research grants from the Swiss National Science 423 
Foundation, the Swiss Heart Foundation, the European Union, the Cardiovascular Research 424 
Foundation Basel, the University Hospital Basel, Abbott, Beckman Coulter, Biomerieux, 425 
BRAHMS, Roche, Nanosphere, Siemens, Singulex, and 8sense. Cohort #2 (ADAPT) was 426 
supported by Queensland Emergency Medicine Research Foundation, Christchurch Heart 427 
21 
 
Institute and Health Research Council and Heart Foundation of New Zealand, Christchurch 428 
Emergency Care Foundation. Cohort #3 (TRAPID-AMI) was sponsored by Roche. 429 
  430 
22 
 
REFERENCES 431 
1.  American College of Emergency Physicians, Society for Cardiovascular Angiography 432 
and Interventions, O’Gara PT, Kushner FG, Ascheim DD, Casey DE, et al. 2013 433 
ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a 434 
report of the American College of Cardiology Foundation/American Heart Association 435 
Task Force on Practice Guidelines. J Am Coll Cardiol [Internet]. 2013 Jan 29 [cited 436 
2014 Jul 10];61(4):e78-140. Available from: 437 
http://www.ncbi.nlm.nih.gov/pubmed/23256914 438 
2.  Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 439 
ESC Guidelines for the management of acute myocardial infarction in patients 440 
presenting with ST-segment elevation: The Task Force for the management of acute 441 
myocardial infarction in patients presenting with ST-segment elevation of the European 442 
Socie. Eur Heart J [Internet]. 2017 Aug 26; Available from: 443 
http://www.ncbi.nlm.nih.gov/pubmed/28886621 444 
3.  Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth 445 
universal definition of myocardial infarction (2018). Eur Heart J [Internet]. 2018 Aug 446 
25; Available from: http://www.ncbi.nlm.nih.gov/pubmed/30165617 447 
4.  Cai Q, Mehta N, Sgarbossa EB, Pinski SL, Wagner GS, Califf RM, et al. The left 448 
bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: 449 
from falsely declaring emergency to denying reperfusion in a high-risk population. Are 450 
the Sgarbossa Criteria ready for prime time? Am Heart J [Internet]. Mosby, Inc.; 2013 451 
Sep [cited 2013 Nov 10];166(3):409–13. Available from: 452 
http://www.ncbi.nlm.nih.gov/pubmed/24016487 453 
5.  Rokos IC, French WJ, Mattu A, Nichol G, Farkouh ME, Reiffel J, et al. Appropriate 454 
Cardiac Cath Lab activation: Optimizing electrocardiogram interpretation and clinical 455 
decision-making for acute ST-elevation myocardial infarction. Am Heart J [Internet]. 456 
Mosby, Inc.; 2010;160(6):995–1003.e8. Available from: 457 
http://dx.doi.org/10.1016/j.ahj.2010.08.011 458 
6.  Larson DM, Menssen KM, Sharkey SW, Duval S, Schwartz RS, Harris J, et al. “False-459 
positive” cardiac catheterization laboratory activation among patients with suspected 460 
ST-segment elevation myocardial infarction. JAMA. 2007;298(23):2754–60.  461 
7.  Erne P, Iglesias JF, Urban P, Eberli FR, Rickli H, Simon R, et al. Left bundle-branch 462 
block in patients with acute myocardial infarction: Presentation, treatment, and trends 463 
in outcome from 1997 to 2016 in routine clinical practice. Am Heart J [Internet]. 2017 464 
Feb;184:106–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28224924 465 
8.  Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early 466 
diagnosis of myocardial infarction with sensitive cardiac troponin assays. [Internet]. 467 
The New England journal of medicine. 2009. Available from: 468 
http://www.ncbi.nlm.nih.gov/pubmed/19710484 469 
9.  Neumann JT, Sörensen NA, Rübsamen N, Ojeda F, Schäfer S, Keller T, et al. Right 470 
bundle branch block in patients with suspected myocardial infarction. Eur Hear journal 471 
Acute Cardiovasc care [Internet]. 2018 Oct 26;2048872618809700. Available from: 472 
http://www.ncbi.nlm.nih.gov/pubmed/30362813 473 
10.  Nestelberger T, Boeddinghaus J, Badertscher P, Twerenbold R, Wildi K, Breitenbücher 474 
D, et al. Effect of Definition on Incidence and Prognosis of Type 2 Myocardial 475 
23 
 
Infarction. J Am Coll Cardiol [Internet]. 2017 Sep 26;70(13):1558–68. Available from: 476 
http://www.ncbi.nlm.nih.gov/pubmed/28935032 477 
11.  Twerenbold R, Boeddinghaus J, Nestelberger T, Wildi K, Rubini Gimenez M, 478 
Badertscher P, et al. Clinical Use of High-Sensitivity Cardiac Troponin in Patients 479 
With Suspected Myocardial Infarction. J Am Coll Cardiol. 2017;70(8).  480 
12.  Boeddinghaus J, Nestelberger T, Twerenbold R, Neumann JT, Lindahl B, Giannitsis E, 481 
et al. Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis 482 
of myocardial infarction. Eur Heart J [Internet]. 2018 Aug 29; Available from: 483 
http://www.ncbi.nlm.nih.gov/pubmed/30169752 484 
13.  Cullen L, Mueller C, Parsonage W a., Wildi K, Greenslade JH, Twerenbold R, et al. 485 
Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-486 
day outcomes in emergency department patients with possible acute coronary 487 
syndrome. J Am Coll Cardiol [Internet]. 2013 Oct 1;62(14):1242–9. Available from: 488 
http://linkinghub.elsevier.com/retrieve/pii/S0735109713014101 489 
14.  Mueller C, Giannitsis E, Christ M, Ordóñez-Llanos J, DeFilippi C, McCord J, et al. 490 
Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial 491 
Infarction With High-Sensitivity Cardiac Troponin T. Ann Emerg Med [Internet]. 2016 492 
Jul 8;68(1):76–87.e4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26794254 493 
15.  Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 494 
2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 495 
[Internet]. 2015;351:h5527. Available from: 496 
http://www.ncbi.nlm.nih.gov/pubmed/26511519 497 
16.  Sgarbossa EB, Pinski SL, Barbagelata A, Underwood DA, Gates KB, Topol EJ, et al. 498 
Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence 499 
of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue 500 
Plasminogen Activator for Occluded Coronary Arteries) Investigators. N Engl J Med 501 
[Internet]. 1996 Feb 22;334(8):481–7. Available from: 502 
http://www.ncbi.nlm.nih.gov/pubmed/8559200 503 
17.  Smith SW, Dodd KW, Henry TD, Dvorak DM, Pearce LA. Diagnosis of ST-elevation 504 
myocardial infarction in the presence of left bundle branch block with the ST-elevation 505 
to S-wave ratio in a modified Sgarbossa rule. Ann Emerg Med [Internet]. Elsevier Inc.; 506 
2012 Dec [cited 2014 Jan 14];60(6):766–76. Available from: 507 
http://www.ncbi.nlm.nih.gov/pubmed/22939607 508 
18.  Meyers HP, Limkakeng AT, Jaffa EJ, Patel A, Theiling BJ, Rezaie SR, et al. 509 
Validation of the modified Sgarbossa criteria for acute coronary occlusion in the setting 510 
of left bundle branch block: A retrospective case-control study. Am Heart J [Internet]. 511 
2015 Dec;170(6):1255–64. Available from: 512 
http://www.ncbi.nlm.nih.gov/pubmed/26678648 513 
19.  Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC 514 
Guidelines for the management of acute coronary syndromes in patients presenting 515 
without persistent ST-segment elevation. Eur Heart J. 2016 Jan;37(3):267–315.  516 
20.  Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter M, Zellweger C, et al. One-517 
hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac 518 
troponin T. Arch Intern Med [Internet]. 2012 Sep;172(16):1211–8. Available from: 519 
http://archinte.jamanetwork.com/article.aspx?articleid=1309579 520 
24 
 
21.  Al-Faleh H, Fu Y, Wagner G, Goodman S, Sgarbossa E, Granger C, et al. Unraveling 521 
the spectrum of left bundle branch block in acute myocardial infarction: insights from 522 
the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) 523 
trials. Am Heart J [Internet]. 2006 Jan;151(1):10–5. Available from: 524 
http://www.ncbi.nlm.nih.gov/pubmed/16368285 525 
22.  Lopes RD, Siha H, Fu Y, Mehta RH, Patel MR, Armstrong PW, et al. Diagnosing acute 526 
myocardial infarction in patients with left bundle branch block. Am J Cardiol 527 
[Internet]. Elsevier Inc; 2011 Sep 15 [cited 2013 Dec 6];108(6):782–8. Available from: 528 
http://www.ncbi.nlm.nih.gov/pubmed/21726838 529 
23.  Kontos MC, Aziz HA, Chau VQ, Roberts CS, Ornato JP, Vetrovec GW. Outcomes in 530 
patients with chronicity of left bundle-branch block with possible acute myocardial 531 
infarction. Am Heart J [Internet]. Mosby, Inc.; 2011 Apr [cited 2014 Jan 532 
14];161(4):698–704. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21473968 533 
24.  Chang AM, Shofer FS, Tabas JA, Magid DJ, McCusker CM, Hollander JE. Lack of 534 
association between left bundle-branch block and acute myocardial infarction in 535 
symptomatic ED patients. Am J Emerg Med [Internet]. Elsevier Inc.; 2009 Oct [cited 536 
2014 Jan 12];27(8):916–21. Available from: 537 
http://www.ncbi.nlm.nih.gov/pubmed/19857407 538 
25.  Pera VK, Larson DM, Sharkey SW, Garberich RF, Solie CJ, Wang YL, et al. New or 539 
presumed new left bundle branch block in patients with suspected ST-elevation 540 
myocardial infarction. Eur Hear journal Acute Cardiovasc care [Internet]. 2018 541 
Apr;7(3):208–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29064258 542 
26.  Dodd KW, Elm KD, Smith SW. Comparison of the QRS Complex, ST-Segment, and 543 
T-Wave Among Patients with Left Bundle Branch Block with and without Acute 544 
Myocardial Infarction. J Emerg Med [Internet]. 2016 Jul 31;51(1):1–8. Available from: 545 
http://www.ncbi.nlm.nih.gov/pubmed/27041492 546 
27.  Neeland IJ, Kontos MC, de Lemos JA. Evolving considerations in the management of 547 
patients with left bundle branch block and suspected myocardial infarction. J Am Coll 548 
Cardiol [Internet]. 2012;60:96–105. Available from: 549 
http://www.ncbi.nlm.nih.gov/pubmed/22766335 550 
28.  Li SF, Walden PL, Marcilla O, Gallagher EJ. Electrocardiographic diagnosis of 551 
myocardial infarction in patients with left bundle branch block. Ann Emerg Med 552 
[Internet]. 2000 Dec;36(6):561–5. Available from: 553 
http://www.ncbi.nlm.nih.gov/pubmed/11097695 554 
29.  Jain S, Ting HT, Bell M, Bjerke CM, Lennon RJ, Gersh BJ, et al. Utility of left bundle 555 
branch block as a diagnostic criterion for acute myocardial infarction. Am J Cardiol 556 
[Internet]. Elsevier Inc.; 2011 Apr 15;107(8):1111–6. Available from: 557 
http://www.ncbi.nlm.nih.gov/pubmed/21296327 558 
30.  Mehta N, Huang HD, Bandeali S, Wilson JM, Birnbaum Y. Prevalence of acute 559 
myocardial infarction in patients with presumably new left bundle-branch block. J 560 
Electrocardiol [Internet]. Elsevier Inc.; 2012 [cited 2013 Dec 6];45(4):361–7. Available 561 
from: http://www.ncbi.nlm.nih.gov/pubmed/22575807 562 
31.  Shlipak MG, Go AS, Frederick PD, Malmgren J, Barron H V, Canto JG. Treatment and 563 
outcomes of left bundle-branch block patients with myocardial infarction who present 564 
without chest pain. National Registry of Myocardial Infarction 2 Investigators. J Am 565 
Coll Cardiol [Internet]. 2000 Sep;36(3):706–12. Available from: 566 
25 
 
http://www.ncbi.nlm.nih.gov/pubmed/10987588 567 
568 
26 
 
Figure Legends  569 
 570 
Flowchart representing the integrated diagnostic work-up for patients presenting with left 571 
bundle branch block and suspected acute myocardial infarction in cohort #1 using hs-cTnT. 572 
AMI: acute myocardial infarction; LBBB: left bundle branch block; (h)s-cTn: (high) 573 
sensitivity-cardiac troponin; pts: patients 574 
 575 
 576 
 577 
Flowchart representing the integrated diagnostic work-up for patients presenting with left 578 
bundle branch block and suspected acute myocardial infarction in cohort #2 using hs-cTnI. 1 579 
Figure 1 Integrated diagnostic work-up in cohort #1 
Figure 2 Integrated diagnostic work-up in cohort #2 
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patient with LBBB and AMI had not all hs-cTnI measurements at presentation and after 2h 580 
available. 581 
AMI: acute myocardial infarction; LBBB: left bundle branch block; (h)s-cTn: (high) 582 
sensitivity-cardiac troponin; pts: patients 583 
 584 
 585 
 586 
Flowchart representing the integrated diagnostic work-up for patients presenting with left 587 
bundle branch block and suspected acute myocardial infarction in cohort #3 using hs-cTnT.  588 
AMI: acute myocardial infarction; LBBB: left bundle branch block; (h)s-cTn: (high) 589 
sensitivity-cardiac troponin; pts: patients 590 
 591 
Figure 3 Integrated diagnostic work-up in cohort #3 
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Table 1 Baseline characteristics in Cohort #1 
       
      
all LBBB (n= 140, 
100%) LBBB no AMI (n=95, 68%) LBBB and AMI (n=45, 32%) p-value no AMI/AMI 
 Age, years, median (IQR) 78 (67 - 84) 74 (63 - 81) 82 (76 - 86) <0.001 
 Male, sex, n % 
 
93 66% 67 71% 26 58% 0.136 
 BMI, median (IQR) 27 (24 - 31) 27 (24 - 31) 25 (22 - 30) 0.60 
 Risk factors, n %                 
 
 
Hypertension 122 87% 80 84% 42 93% 0.132 
 
 
Hypercholesterolemia 92 66% 58 61% 34 76% 0.091 
 
 
Diabetes 
 
25 18% 14 15% 11 25% 0.143 
 
 
Current smoking 16 11% 10 11% 6 13% 0.63 
 
 
History of smoking 67 48% 42 44% 25 56% 0.209 
 History, n %                 
 
 
Coronary artery disease 76 54% 41 43% 35 78% <0.001 
 
 
Previous myocardial infarction 54 39% 26 27% 28 62% <0.001 
 
 
Previous revascularization 54 39% 33 35% 21 47% 0.176 
 
 
Peripheral artery disease 12 8.6% 4 4·2% 8 18% 0.007 
 
 
Previous stroke 16 11% 7 7·4% 9 20% 0.028 
 
 
Positive family history 21 17% 17 20% 4 11% 0.27 
 Medication at entry, n %               
 
 
Aspirin/Thienopyridin 77 55% 49 52% 28 62% 0.24 
 
 
Betablockers 
 
74 53% 47 50% 27 60% 0.24 
 
 
ACE/AT2- Inhibitors 92 66% 57 60% 35 78% 0.038 
 
 
Ca- Antagonists 31 22% 16 17% 15 33% 0.028 
 
 
Marcoumar/Warfarin 27 19% 17 18% 10 22% 0.54 
 
 
Nitrates 
 
37 26% 21 22% 16 36% 0.092 
 Measurements/Findings               
 
 
Systolic BP, median (IQR) 136 (118 - 161) 138 (121 - 163) 134 (115 - 152) 0.110 
 
 
Pulse, median (IQR) 82 (67 - 96) 78 (64 - 90) 88 (75 - 99) 0.011 
 
 
eGFR, mL/min/m2, median 69 (48 - 86) 77 (60 - 91) 47 (35 - 69) <0.001 
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(IQR) 
 
BNP pg/ml, median (IQR) 672 (199 - 1272) 421 (168 - 1121) 919 (327 - 1643) 0.105 
 Coronary Angiography n (%) 49 35% 24 25% 25 56% <0.001 
 
 
One vessel disease 4 2.9% 3 3.2% 1 2.2% 1.000 
 
 
Two vessel disease 12 8.6% 2 2.1% 10 22% <0.001 
  Three vessel disease 21 15% 7 7.4% 14 31% 0.001 
 Coronary Intervention n (%) 20 14% 4 4.2% 16 36% <0.001 
 
 
Left main vessel 0 0.0% 0 0.0% 0 0.0% n.a. 
 
 
RIVA 
 
7 5.0% 0 0.0% 7 16% <0.001 
 
 
RCX 
 
8 5.7% 2 2.1% 6 13% 0.014 
 
 
ACD 
 
3 2.1% 1 1.1% 2 4.4% 0.24 
 
 
Bypass Intervention 6 4.3% 2 2.1% 4 8.9% 0.084 
 
 
More than one intervention 3 1.1% 1 1.1% 2 4.4% 0.24 
 CABG   3 2.1% 0 0.0% 3 6.7% 0.032 
 Table Legends: LBBB: left bundle branch block; IQR: interquartile range; ACE: angiotensin converting enzyme; AT1: angiotension 1;  
 Ca: Calcium; ACS: acute coronary syndrome; BP: blood pressure; eGFR: estimated glomerular filtration rate; RIVA: Ramus interventricularis 
anterior; 
 RCX: Ramus circumflexus; ACD: Arteria coronaria dextra; CABG: coronary artery 
bypass graft 
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 601 
Table 2 Diagnostic performance of ECG criteria in all cohorts 
 
 true-
positive 
test 
result 
false-
negativ
e test 
result 
true-
negati
ve test 
result 
false-
positiv
e test 
result 
Accuracy %        
(95% CI) 
Sensitivity % 
(95% CI) 
Specificity %     
(95% CI) 
NPV %               
(95% CI) 
PPV %                
(95% CI) all cohorts 
ECG criteria 1 (5 points) 1 74 172 0 70% (64 - 76%) 1% (0 - 7%) 100% (98 - 100%) 70% (64 - 75%) 100% (21 - 100%) 
ECG criteria 2 (3 points) 2 73 171 1 70% (64 - 76%) 3% (1 - 9%) 99% (97 - 100%) 70% (64 - 76%) 67% (21 - 94%) 
ECG criteria 3 (2 points) 5 70 164 8 68% (62 - 74%) 7% (2 - 15%) 95% (91 - 98%) 70% (64 - 76%) 39% (18 - 65%) 
ECG Score ≥ 3 points 2 73 171 1 70% (64 - 76%) 3% (0 - 9%) 99% (97 - 100%) 70% (69 - 71%) 67% (16 - 96%) 
Alternative ECG criteria 1 
(2 points) 8 67 169 3 72% (66 - 77%) 11% (5 - 20%) 98% (95 - 100%) 72% (66 - 77%) 72% (42 - 91%) 
Alternative ECG Score ≥ 3 
points 9 66 166 6 71% (65 - 76%) 12% (6- 22%) 97% (93 - 99%) 72% (70 - 73%) 60% (36 - 80%) 
Table legends: AUC: area under the curve; CI: confidence interval; NPV: negative predictive value; PPV: positive 
predictive value, n.a.: not applicable 
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Table 3 Diagnostic performance hs-cTn (T and I) and s-cTnI in LBBB patients in all 3 cohorts 
cohort #1 AUC (95% CI) 
Cutoff values 
for PPV 80%  
patients, 
n 
 true-
positive 
test 
result, n 
false-
negative 
test 
result, n 
true-
negative 
test 
result, n 
false-
positive 
test 
result, 
n 
Sensitivity %         
(95% CI) 
Specificity %       
(95% CI) 
NPV %                  
(95% CI) 
PPV %                 
(95% CI) 
hs-cTnT 0h 0.91 
(0.85 - 
0.96) ≥42ng/L 140 36 9 86 9 
80% (66 - 
89%) 
91% (83 - 
95%) 
91% (83 - 
95%) 80% (66 - 89%) 
hs-cTnT Abs 
Change 0h/1h 0.91 
(0.84 - 
0.98) ≥3ng/L 120 32 6 75 7 
84% (70 - 
93%) 
92% (83 - 
96%) 
93% (85 - 
97%) 82% (67 - 91%) 
hs-cTnI 0h 0.89 
(0.83 - 
0.95) ≥45ng/L 132 29 13 83 7 
69% (54 - 
81%) 
92% (85 - 
96%) 
87% (78 - 
92%) 81% (65 - 90%) 
hs-cTnI Abs 
Change 0h/1h 0.96 
(0.91 - 
1.00) ≥4ng/L 111 30 3 71 7 
91% (76 - 
97%) 
91% (83 - 
96%) 
96% (89 - 
99%) 81% (66 - 91%) 
s-cTnI 0h 0.97 
(0.94 - 
1.00) ≥53ng/L 87 28 4 49 6 
87% (72 - 
95%) 
89% (78 - 
95%) 
93% (82 - 
97%) 82% (66 - 92%) 
s-cTnI Abs Change 
0h/1h 0.93 
(0.85- 
1.00) ≥10ng/L 75 21 4 45 5 
84% (65 - 
94%) 
90% (79 - 
96%) 
92% (81 - 
97%) 81% (62 - 92%) 
cohort #2                         
hs-cTnT 0h 0.96 (0.85-0.99) ≥42ng/L 45 9 3 31 2 
75% (43-
95%) 94% (80-99%) 
91% (76-
98%) 82% (48-98%) 
hs-cTnT Abs 
Change 0h/2h 0.89 
 (0.74-
0.96) ≥3ng/L 42 9 3 24 6 
75% (43-
95%) 80% (61-92%) 
89% (71-
98%) 60% (32-84%) 
hs-cTnI 0h 0.93 (0.83-0.98) ≥45ng/L 56 13 3 36 4 
81% (56-
94%) 90% (80-93%) 
92% (79-
98%) 78% (54-89%) 
hs-cTnI Abs 
Change 0h/2h 0.95 (0.85-0.99) ≥4ng/L 56 15 1 33 7 
94% (70-
100%) 83% (67-93%) 
97% (85-
100%) 68% (45-86%) 
cohort #3                         
hs-cTnT 0h 0.81 
(0.67 - 
0.95) ≥42ng/L 37 6 7 23 1 
46% (23 - 
71%) 
96% (80 - 
99%) 
77% (59 - 
88%) 86% (49 - 97%) 
hs-cTnT Abs 
Change 0h/1h 0.88 
(0.77 - 
0.99) ≥3ng/L 37 10 3 17 7 
77% (50 - 
92%) 
71% (51 - 
85%) 
85% (64 - 
95%) 59% (36 - 78%) 
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s-cTnI 0h 0.96 
(0.91 - 
1.00) ≥53ng/L 36 1 11 24 0 8% (1 - 35%) 
100% (86 - 
100%) 
69% (52 - 
81%) 
100% (21 - 
100%) 
s-cTnI Abs Change 
0h/1h 0.92 
(0.81 - 
1.00) ≥11ng/L 36 9 3 23 1 
75% (47 - 
91%) 
96% (80 - 
99%) 
88% (71 - 
96%) 90% (60 - 98%) 
Table legends: LBBB: left bundle branch block; hs-cTn: high sensitivity cardiac troponin: AUC: area under the curve; CI: confidence interval; NPV: 
negative predictive value; PPV: positive predictive value   
n: number of 
patients 
           
  
